Filing Details

Accession Number:
0001209191-21-035596
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-05-24 21:25:43
Reporting Period:
2021-05-20
Accepted Time:
2021-05-24 21:25:43
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1706431 Vir Biotechnology Inc. VIR () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1207792 J Robert More C/O Vir Biotechnology, Inc.
499 Illinois Street, Suite 500
San Francisco CA 94158
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-05-20 2,575 $43.57 98,430 No 4 S Direct
Common Stock Disposition 2021-05-20 9,095 $44.77 89,335 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 486,111 Indirect See footnote
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.16 to $44.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
  3. Includes 30,354 shares received in a pro-rata distribution from Alta Partners NextGen Fund I, L.P. (APNG 1) which was effected on April 5, 2021.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.22 to $45.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
  5. The shares are held by APNG 1. The reporting person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG 1. As such, the reporting person may be deemed to beneficially own the shares held by APNG 1. However, the reporting person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed to be an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. On April 5, 2021, APNG 1 effected, without consideration, a pro-rata in-kind distribution of 486,110 shares to its partners. In prior reports, the reporting person reported indirect beneficial ownership of 972,221 shares of the Issuer held by APNG 1.